Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
CGEM Stock Forecast 2026-2027
$17.69
Current Price
$1.10B
Market Cap
Buy 12
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to CGEM Price Targets
+114.8%
To High Target of $38.00
+69.6%
To Median Target of $30.00
+35.7%
To Low Target of $24.00
CGEM Price Momentum
-2.4%
1 Week Change
+17.7%
1 Month Change
+134.9%
1 Year Change
+70.9%
Year-to-Date Change
-9.0%
From 52W High of $19.43
+211.4%
From 52W Low of $5.68
📊 TOP ANALYST CALLS
Did CGEM Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Cullinan is one of their latest high-conviction picks.
Latest CGEM Stock Price Targets & Analyst Predictions
Based on our analysis of 7 Wall Street analysts, CGEM has a bullish consensus with a median price target of $30.00 (ranging from $24.00 to $38.00). The overall analyst rating is Strong Buy (9.8/10). Currently trading at $17.69, the median forecast implies a 69.6% upside. This outlook is supported by 12 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Julian Harrison at BTIG, projecting a 114.8% upside. Conversely, the most conservative target is provided by Robert Burns at HC Wainwright & Co., suggesting a 35.7% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CGEM Analyst Ratings
12
Buy
0
Hold
0
Sell
CGEM Price Target Range
Low
$24.00
Average
$30.00
High
$38.00
Current: $17.69
Latest CGEM Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CGEM.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jun 11, 2026 | Wedbush | Robert Driscoll | Outperform | Reiterates | $37.00 |
| Jun 8, 2026 | HC Wainwright & Co. | Robert Burns | Buy | Reiterates | $30.00 |
| May 19, 2026 | BTIG | Buy | Reiterates | $N/A | |
| May 8, 2026 | Wedbush | Outperform | Maintains | $N/A | |
| May 4, 2026 | BTIG | Buy | Reiterates | $N/A | |
| Apr 28, 2026 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Apr 28, 2026 | BTIG | Buy | Reiterates | $N/A | |
| Mar 11, 2026 | Wedbush | Outperform | Maintains | $N/A | |
| Feb 17, 2026 | Citigroup | Buy | Initiates | $N/A | |
| Feb 2, 2026 | Guggenheim | Buy | Initiates | $N/A | |
| Jan 8, 2026 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Dec 9, 2025 | Wedbush | Outperform | Maintains | $N/A | |
| Nov 24, 2025 | BTIG | Julian Harrison | Buy | Maintains | $38.00 |
| Nov 20, 2025 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Sep 12, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Sep 10, 2025 | BTIG | Buy | Reiterates | $N/A | |
| Aug 21, 2025 | HC Wainwright & Co. | Robert Burns | Buy | Assumes | $24.00 |
| Aug 18, 2025 | Morgan Stanley | Overweight | Maintains | $N/A | |
| Jun 11, 2025 | Stifel | Alex Thompson | Buy | Reinstates | $22.00 |
| May 12, 2025 | UBS | Buy | Maintains | $N/A |
Cullinan Therapeutics, Inc. (CGEM) Competitors
The following stocks are similar to Cullinan based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Cullinan Therapeutics, Inc. (CGEM) Financial Data
Cullinan Therapeutics, Inc. has a market capitalization of $1.10B with a P/E ratio of 9.0x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -48.2%.
Valuation Metrics
Market Cap
$1.10B
Enterprise Value
$748.75M
P/E Ratio
9.0x
PEG Ratio
6.7x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+32.4%
Current Ratio
10.3x
Debt/Equity
0.7x
ROE
-48.2%
ROA
-30.6%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Cullinan Therapeutics, Inc. (CGEM) Business Model
About Cullinan Therapeutics, Inc.
What They Do
Develops targeted therapies for cancer treatment.
Business Model
Cullinan Therapeutics Inc. operates as an early-stage biopharmaceutical company focusing on innovative cancer treatments, primarily through immuno-oncology and precision medicine. The company generates revenue by developing a diversified pipeline of targeted therapies aimed at specific genetic mutations and tumor mechanisms, addressing unmet medical needs in oncology.
Additional Information
With a commitment to innovation and strategic drug development, Cullinan plays a vital role in advancing cancer treatment options. Its portfolio includes several therapeutic assets in early development stages, positioning the company as a key player in the growing market for targeted cancer therapies.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
109
CEO
Mr. Nadim Ahmed M.S.
Country
United States
IPO Year
2021
Website
cullinantherapeutics.comCullinan Therapeutics, Inc. (CGEM) Latest News & Analysis
Latest News
Quick Summary
Cullinan Therapeutics, Inc. (CGEM) presented encouraging clinical data for its treatments CLN-978 and Velinotamig targeting autoimmune diseases.
Why It Matters
Promising clinical data for CGEM's therapies could indicate potential market success, impacting stock performance and investor sentiment in biotech.
Source: Seeking Alpha
Market Sentiment:
Positive
Quick Summary
CLN-978 (CD19 TCE) showed potential for immune reset and remissions in systemic lupus erythematosus and rheumatoid arthritis, according to EULAR data.
Why It Matters
Positive EULAR data on CLN-978 suggests potential breakthroughs in treating SLE and RA, which could drive stock performance for the company and attract investor interest in biotech.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Cullinan Therapeutics: Heading Toward Paydirt
1 month ago
Quick Summary
Cullinan Therapeutics is viewed as a strong buy as zipalertinib nears an FDA decision for NSCLC. Promising phase 3 data and a solid pipeline support positive outlook.
Why It Matters
Cullinan Therapeutics' promising zipalertinib, strong pipeline, and solid cash position suggest potential growth, making it an attractive opportunity for investors seeking biotech exposure.
Source: Seeking Alpha
Market Sentiment:
Positive
Quick Summary
The company will present new clinical data from studies on systemic lupus erythematosus and rheumatoid arthritis, including initial data from multi-dose cohorts, at an event for investors on June 10 in NYC.
Why It Matters
New clinical data on SLE and RA could influence drug efficacy perceptions, impacting stock prices and investor sentiment for the involved biotech companies.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
CLN-049, a novel FLT3xCD3 T cell engager, has received Orphan Drug Designation, highlighting its potential to meet unmet needs in acute myeloid leukemia (AML).
Why It Matters
Orphan Drug Designation for CLN-049 highlights its potential market advantage in AML treatment, signaling possible future revenue growth and increased investor interest in the biotech sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Cullinan Therapeutics (Nasdaq: CGEM) will present initial clinical data for its CD19xCD3 T cell engager, CLN-978, at the EULAR Congress in London from June 3-6, 2026.
Why It Matters
Initial clinical data on CLN-978 could indicate its efficacy and potential market position, impacting Cullinan Therapeutics' stock performance and investor sentiment in the biotech sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About CGEM Stock
What is Cullinan Therapeutics, Inc.'s (CGEM) stock forecast for 2027?
Based on our analysis of 7 Wall Street analysts, Cullinan Therapeutics, Inc. (CGEM) has a median price target of $30.00. The highest price target is $38.00 and the lowest is $24.00.
Is CGEM stock a good investment in 2027?
According to current analyst ratings, CGEM has 12 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $17.69. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for CGEM stock?
Wall Street analysts predict CGEM stock could reach $30.00 in the next 12 months. This represents a 69.6% increase from the current price of $17.69. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Cullinan Therapeutics, Inc.'s business model?
Cullinan Therapeutics Inc. operates as an early-stage biopharmaceutical company focusing on innovative cancer treatments, primarily through immuno-oncology and precision medicine. The company generates revenue by developing a diversified pipeline of targeted therapies aimed at specific genetic mutations and tumor mechanisms, addressing unmet medical needs in oncology.
What is the highest forecasted price for CGEM Cullinan Therapeutics, Inc.?
The highest price target for CGEM is $38.00 from Julian Harrison at BTIG, which represents a 114.8% increase from the current price of $17.69.
What is the lowest forecasted price for CGEM Cullinan Therapeutics, Inc.?
The lowest price target for CGEM is $24.00 from Robert Burns at HC Wainwright & Co., which represents a 35.7% increase from the current price of $17.69.
What is the overall CGEM consensus from analysts for Cullinan Therapeutics, Inc.?
The overall analyst consensus for CGEM is bullish. Out of 7 Wall Street analysts, 12 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $30.00.
How accurate are CGEM stock price projections?
Stock price projections, including those for Cullinan Therapeutics, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 18, 2026 2:15 AM UTC